Kyntra Bio Statistics
Kyntra Bio (1FG0) Stock Statistics & Valuation Metrics
Total Valuation
Kyntra Bio has a market cap or net worth of EUR 12.94M. The enterprise value is -EUR 38.76M.
- Market Cap
- EUR 12.94M
- Enterprise Value
- -EUR 38.76M
Share Statistics
Kyntra Bio has 4,049,124 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,049,124
- Owned by Insiders
- 3.37%
- Owned by Institutions
- 26.51%
Financial Efficiency
Kyntra Bio’s return on equity (ROE) is -6.11 and return on invested capital (ROIC) is -50.72%.
- Return on Equity (ROE)
- -6.11
- Return on Assets (ROA)
- 1.53
- Return on Invested Capital (ROIC)
- -50.72%
- Return on Capital Employed (ROCE)
- -0.51
- Revenue Per Employee
- 189.41K
- Profits Per Employee
- 5.40M
- Employee Count
- 34
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.15
Valuation Ratios
The current PE Ratio of Kyntra Bio is 0.06. Kyntra Bio’s PEG ratio is 0.00.
- PE Ratio
- 0.06
- PS Ratio
- 3.13
- PB Ratio
- -0.48
- Price to FCF
- -0.38
- Price to Operating Cash Flow
- -0.38
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.
- Revenue
- 6.44M
- Gross Profit
- 5.88M
- Operating Income
- -45.90M
- Pretax Income
- -58.29M
- Net Income
- 183.45M
- EBITDA
- -57.55M
- Earnings Per Share (EPS)
- 45.37
Cash Flow
In the last 12 months, operating cash flow was -38.05M and capital expenditures -9,000, giving a free cash flow of -38.06M billion.
- Operating Cash Flow
- -38.05M
- Free Cash Flow
- -38.06M
- Free Cash Flow per Share
- -9.40
Dividends & Yields
Kyntra Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -241.03%
- Earnings Yield
- 1160.38%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- -65.81%
- 50-Day Moving Average
- 5.33
- 200-Day Moving Average
- 5.78
- Relative Strength Index (RSI)
- 19.52
- Average Volume (3m)
- 85
Important Dates
Kyntra Bio upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of 0.00%
- Current Ratio
- 3.39
- Quick Ratio
- 3.26
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.83
- Interest Coverage Ratio
- -5.24
Taxes
In the past 12 months, Kyntra Bio has paid -90.00K in taxes.
- Income Tax
- -90.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Kyntra Bio EV to EBITDA ratio is 0.37, with an EV/FCF ratio of 0.92.
- EV to Sales
- -7.55
- EV to EBITDA
- 0.37
- EV to Free Cash Flow
- 0.92
- EV to Operating Cash Flow
- 0.92
Balance Sheet
Kyntra Bio has EUR 91.32M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 91.32M billion.
- Cash & Marketable Securities
- EUR 91.32M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 91.32M
- Net Cash Per Share
- EUR 22.55
- Tangible Book Value Per Share
- -EUR 2.01
Margins
Gross margin is 18.15%, with operating margin of -1101.02%, and net profit margin of 3967.77%.
- Gross Margin
- 18.15%
- Operating Margin
- -1101.02%
- Pretax Margin
- -669.57%
- Net Profit Margin
- 3967.77%
- EBITDA Margin
- -2036.00%
- EBIT Margin
- -2040.61%
Analyst Forecast
The average price target for Kyntra Bio is EUR 34.47, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 34.47
- Price Target Upside
- 983.99% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -91.93%
- EPS Growth Forecast
- ―
